Exploring barriers and opportunities for Black, Indigenous, and People of Color (BIPOC) therapists in psychedelic-assisted therapy: A qualitative study
Yvan Beaussant, Candace Oglesby, Kim Roddy, Justin J. Sanders, Manish Agrawal
Journal of Psychedelic Studies March 1, 2026 DOI: 10.1556/2054.2025.00460 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Qualitative study Peer reviewed |
|---|---|
| Sample size | 18 |
| Population | Licensed therapists and healthcare professionals identifying as BIPOC |
| Topics | Psychedelic-assisted therapy |
| Key findings | BIPOC therapists identified opportunities to enhance diversity and cultural attunement in psychedelic-assisted therapies, but face barriers including financial and geographic inaccessibility of training, exclusionary environments, stigma, and extractive therapeutic models. |
Abstract
Abstract Background and aims Psychedelic-assisted therapies (PAT) have emerged as promising treatments for mental health conditions such as depression, anxiety, and trauma-related disorders. However, the underrepresentation of Black, Indigenous, and People of Color (BIPOC) in PAT research and clinical practice limits equitable access and the generalizability of outcomes. This study explored the perspectives of BIPOC therapists on opportunities and barriers to engaging in PAT, with the aim of identifying strategies to foster inclusivity and equity in the field.
Methods: Using a qualitative design, we conducted semi-structured interviews and focus groups with 18 licensed therapists and healthcare professionals identifying as BIPOC. Data collection explored participants' experiences with PAT, perceived barriers and opportunities, and perspectives on cultural diversity within the field. Template analysis was conducted on transcribed audio recordings.
Results: Key ‘Opportunities’ themes included the potential for BIPOC therapists to enhance diversity in PAT, foster safety and trust for clients of color, and provide culturally attuned care to address trauma rooted in systemic oppression. Participants identified ‘Barriers’ such as financial and geographic inaccessibility of training, exclusionary training environments, stigma associated with psychedelics, and the extractive nature of current Western therapeutic models. To address these challenges, participants recommended culturally responsive training programs, mentorship opportunities, financial support, and community education to reduce stigma and increase engagement. Most participants identified as African American/Black, which may limit transferability of findings to other BIPOC groups.
Conclusion: This study underscores the critical role of BIPOC therapists in advancing equity and cultural responsiveness in PAT and highlights the need for intentional efforts to create equitable, culturally informed models of care.
Comparable studies
Other qualitative studies on psychedelic-assisted therapy, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression enrolled in an open-label trial of psilocybin | 2017 | Qualitative study | n = 20 |
| LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects Patients with anxiety associated with life-threatening diseases | 2014 | Prospective follow-up with qualitative content analysis | n = 10 |
| Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis Adults aged 22 to 69 with clinically elevated anxiety associated with a cancer diagnosis | 2017 | Qualitative study | n = 13 |
| Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts Participants who completed a psilocybin-facilitated smoking cessation pilot study | 2018 | Qualitative follow-up study using semi-structured interviews and thematic analysis | n = 12 |
| The hidden therapist: evidence for a central role of music in psychedelic therapy Patients undergoing psychedelic therapy with psilocybin for treatment-resistant depression | 2018 | Qualitative study | n = 19 |
Citations in the library
Cites 19
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
and 14 more in the library